On September 5th, the U.S. FDA granted full approval for our medicine to slow kidney function decline in adults with IgA nephropathy. For more information, see our Press Release.
Search for information about a product, therapeutic area or event
Media, investors, advocacy organizations and others, please contact us here.
For US healthcare professionals only
The purpose of this Travere Therapeutics Medical Affairs website is to support healthcare professionals with scientific information. This website is also a channel for US healthcare professionals to submit questions or connect with Travere Therapeutics US healthcare professionals. The information provided is for educational purposes only and is not intended to promote any products. By continuing to use this site you are acknowledging that you are a US healthcare professional
A USRDS Retrospective Cohort Study: Epidemiology, Treatment Modalities, and Burden of End-StageKidney Disease Attributed to Focal Segmental Glomerulosclerosis (FSGS)
A USRDS Retrospective Cohort Study: Epidemiology, Treatment Modalities, and Burden of End-Stage Kidney Disease Attributed to Focal Segmental Glomerulosclerosis (FSGS)
Focal Segmental Glomerulosclerosis (FSGS) In Adults: A Retrospective Analysis Of USPrevalence And Impacts Of Proteinuria And Kidney Function Decline On Healthcare ResourceUtilization (HRU) And Costs
Focal Segmental Glomerulosclerosis (FSGS) In Adults: A Retrospective Analysis Of US PrevalenceAnd Impacts Of Proteinuria And Kidney Function Decline On Healthcare Resource Utilization (HRU)And Costs
Sparsentan Protects the GlomerularBasement Membrane and Glycocalyx, andAttenuates Proteinuria in a Rat Model ofFocal Segmental Glomerulosclerosis (FSGS)
Baseline Characteristics of PatientsEnrolled in the Ongoing Phase 3Randomized, Double-Blind, Active-Control Trial of Sparsentan for theTreatment of Focal SegmentalGlomerulosclerosis (DUPLEX)